Biology and Management of Multiple Myeloma
Author: James Berenson
Publisher:
Published: 2014-01-15
Total Pages: 380
ISBN-13: 9781468498714
DOWNLOAD EBOOK →Lanterna Rally
eBook PDF Download Digital Library
Biology and Management of Multiple Myeloma
Author: James R. Berenson
Publisher: Springer Science & Business Media
Published: 2004-05-14
Total Pages: 375
ISBN-13: 159259817X
DOWNLOAD EBOOK →Expert physicians and clinical researchers summarize and explain all the recent advances in the biology and treatment of bone marrow-based malignancy. On the biological side, the authors show the characteristics of the malignant cell and describe the significant roles played by oncogenic changes, chromosomal anomalies, Kaposi's sarcoma herpes virus, and cytokines. New epidemiological findings and prognostic factors are also analyzed. On the clinical side, the authors provide a comprehensive review of conventional treatment regimens, as well as a discussion of newer experimental approaches involving immunologic targeting, inhibitors of drug resistance, and antitumor agents.
Advances in Biology and Therapy of Multiple Myeloma
Author: Nikhil C. Munshi
Publisher: Springer Science & Business Media
Published: 2012-11-15
Total Pages: 322
ISBN-13: 146144666X
DOWNLOAD EBOOK →Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patients with MM.
Myeloma Therapy
Author: Sagar Lonial
Publisher: Springer Science & Business Media
Published: 2009-01-01
Total Pages: 674
ISBN-13: 1597455644
DOWNLOAD EBOOK →Therapeutic options for patients with myeloma have dramatically changed over the past 10 years. Beginning with the advances in therapy resulting from the use of high-dose therapy and autologous bone marrow or stem cell tra- plant, we have more than doubled the median survival for patients as a whole, and have now have a wealth of different biology -based treatment approaches for our patients in all disease stages. This book represents state-of-the-art information from many of the leaders in the plasma cell disorders world. Sections focusing on disease pathogenesis and biology, chemotherapy-based approaches, immune -based therapies, currently approved novel agents, developing targets, supportive care, and other plasma cell disorders provides a comprehensive collection and an excellent resource in this time of rapid change in clinical and preclinical disease knowledge. It is important to realize that these changes did not occur in a vacuum. Partnerships between academic institutions, the pharmaceutical industry, patient advocacy groups, the National Cancer Institute, community onco- gists, and ultimately our patients worked closely together to realize these advances, and to effect the radical changes in therapy we have witnessed over the past few years. This book would not have been possible without contri- tions from each of the gifted scientists and clinicians who worked tirelessly to prepare their individual chapters all the while maintaining commitment to the scientific and clinical mission of advancing care.
Multiple Myeloma
Author: Morie A. Gertz
Publisher: Springer Science & Business Media
Published: 2013-10-01
Total Pages: 311
ISBN-13: 1461485207
DOWNLOAD EBOOK →This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers all aspects of multiple myeloma, from molecular classification and diagnosis, to risk stratification and therapy. Closely related plasma cell disorders such as solitary plasmacytoma, Waldenstrom macroglobulinemia, and light chain amyloidosis are discussed in detail as well. The book addresses often overlooked topics, including the role of radiation therapy, vertebral augmentation, and supportive care. Our understanding of this group of disorders is developing at an unprecedented rate, and Multiple Myeloma meets the need among oncologists and hematologists for a clear, timely, and authoritative resource on their biology, diagnosis, and treatment.
Myeloma
Author: J. S. Malpas
Publisher: Elsevier Health Sciences
Published: 2004
Total Pages: 472
ISBN-13:
DOWNLOAD EBOOK →This book was prompted by a renewed interest in the biology of myeloma, new concepts with regard to its clinical evolution, and options for therapy that have not been available before. Myeloma has always involved many systems and caused many problems for the clinician. It has become a focus of attention for the scientist and clinician.
Biology and Management of Unusual Plasma Cell Dyscrasias
Author: Todd M. Zimmerman
Publisher: Springer
Published: 2016-09-17
Total Pages: 202
ISBN-13: 1441968482
DOWNLOAD EBOOK →This unique book focuses on the non-myeloma plasma cell dyscrasias. A key resource for this group of diseases, the book features the latest in emerging knowledge and therapeutic developments, including novel therapies. Each disease-specific chapter discusses biology, disease course, and appropriate therapeutic interventions, covering plasma cell leukemia, plasmacytoma, POEMS Syndrome and Castleman's Disease, Waldenström macroglobulinemia, immunoglobin deposition disease, and cryoglobulinemic syndromes, among others. The only book dedicated to this intriguing family of diseases, Biology and Management of Unusual Plasma Cell Dyscrasias will be a long-lasting reference for clinicians and scientists alike.
Epidemiology and Biology of Multiple Myeloma
Author: G. Iris Obrams
Publisher: Springer Science & Business Media
Published: 2012-12-06
Total Pages: 186
ISBN-13: 3642766552
DOWNLOAD EBOOK →On March 27, 1990, the National Cancer Institute sponsored a workshop on the epidemiology of multiple myeloma, held at the National Institutes of Health. This book comprises articles prepared by participants in this work shop. Discussed in these papers are: the descriptive and analytic epidemi ology, differences in risk factors between blacks and whites, monoclonal gammopathies and their progression, and hypotheses regarding the etiology and pathogenesis of multiple myeloma. Several epidemiologic research areas received particular attention during this workshop, and are reviewed in detail in this volume. There have been striking increases in the incidence of multiple myeloma over the past thirty years, especially among older individuals and blacks, which may not be entirely explained by changes in diagnostic capabilities. Occupational and environmental exposures have been associated with an increased risk of multiple myeloma, including farming exposures, occupational exposure to petroleum and rubber processing, exposure to ionizing radiation, and asso ciations with persistent virus infections. The most striking epidemiological finding is reflected in the differences in incidence rates of multiple myeloma which are twice as high in blacks as compared with whites. Further, since 1950 the mortality rates for multiple myeloma have quadrupled in blacks while doubling for whites. Among hematopoietic malignancies, multiple myeloma is the only one with increased incidence and mortality rates among blacks. 1\vo major possibilities for explaining ethnic/racial differences in suscepti bility to multiple myeloma are genetic and environmental factors.
Advances in Biology and Therapy of Multiple Myeloma
Author: Nikhil C. Munshi
Publisher: Springer
Published: 2015-01-28
Total Pages: 0
ISBN-13: 9781489989147
DOWNLOAD EBOOK →Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patients with MM.
Contemporary Management of Multiple Myeloma
Author: Ravi Vij
Publisher: JAYPEE BROTHERS MEDICAL PUBLISHERS PVT. LTD.
Published: 2012-12-15
Total Pages: 227
ISBN-13: 9350905442
DOWNLOAD EBOOK →This book "Contemporary Management of Multiple Myeloma" discusses in detail about the management of multiple myeloma. Multiple Myeloma is the second most common hematological malignancy in the United States. This book highlights the interplay between the malignant plasma cell and the microenvironment, and the role of genetic alterations, adhesion molecules and critical cytokines in this complex milieu. The first chapter of this book discusses epidemiology, etiology and pathogenesis of multiple myeloma. The clinical presentation of the common plasma cell dyscrasias and discuss the diagnostic and prognostic work-up with a highlighting on recent advances in chapters 3 and 4. Chapters from 5 to 9 focus on the therapeutic evolution that has occurred, and accumulate the landmark clinical trials that have changed clinical practice for up-front treatment of both transplant eligible and ineligible patients and for those with relapsed and refractory disease. These chapters also highlights on the important role of clinical research with stem cell transplantation, proteasome-inhibition and immunomodulatory drugs that form the backbone of our present day therapeutic armamentarium. Recommendations for response assessment and current understanding of the value of maximizing the depth of response in personalized therapy and patient segmentation are briefly explained in chapters 10 and 11. Chapter 12 and 13 discussed about adjunctive treatment modalities and novel therapeutic compounds in clinical trial and targets for future drug development. This book provides complete information about current landscape for multiple myeloma which is helpful in future aspects.
